ACTRN12615001048572尚未招募4 期
Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsy
Anne Trinh0 个研究点目标入组 40 人开始时间: 2015年10月7日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •aged greater or equal to 18 years
- •cerebral palsy
- •non ambulatory (includes those who can stand for transfers only).
- •Z score at lumbar spine or proximal femur less or equal to -2.0
排除标准
- •-Secondary cause for bone disease (hypoparathyroidism, hyperparathyroidism, hypothyroidism, hyperthyroidism, rheumatoid arthritis, Paget’s disease
- •-Hypocalcaemia/hypercalcaemia
- •-Previous use of bisphosphonates in the last 2 years
- •-Current use of medication to treat osteoporosis: strontium, denosumab
- •-Use of glucocorticoids (washout period of 1 year)
- •-Calculated creatinine clearance of <30ml/min as per Cockcroft Gault equation
- •-Pregnancy (F)
- •-Post-menopausal (F)
- •-Current use of medications that can increase risk of renal dysfunction: diuretics, aminoglycosides
研究者
相似试验
已完成
不适用
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate CancerBone DensityProstatic NeoplasmsNCT00489905Hospital Authority, Hong Kong24
进行中（未招募）
1 期
Zoledronic acid for prevention of bone loss after bariatric surgeryMorbid obese subjects undergoing bariatric surgeryEUCTR2019-001650-26-DKHospital South West Jutland70
Unknown
不适用
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke PatientsStrokeNCT04652128Yonsei University56
进行中（未招募）
1 期
Study to investigate changes in BMD of the lumbar spine (LS) one year after treatment discontinuation in denosumab-treated women and in denosumab-treated women who received a single infusion of zoledronic acid after treatment discontinuation.EUCTR2016-000852-91-NLeiden University Medical Center75
已完成
不适用
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmabOsteoporosisNL-OMON43199eids Universitair Medisch Centrum30